Plain-English translation of NCT05265429 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a research study that aims to understand why lung cancer develops in people age 45 and younger — a relatively rare situation. Researchers will collect blood, saliva, and tumor tissue samples from participants to examine genetic patterns and risk factors that may explain lung cancer in young adults. The goal is to improve screening and treatment options specifically for this younger population.
Lung cancer in people under 45 is uncommon, and doctors don't fully understand why some young people develop it, especially those who have never smoked. By studying the genetics and characteristics of these cancers, researchers hope to identify new ways to catch the disease earlier and develop better treatments tailored to younger patients.
You likely qualify if…
You likely don't qualify if…
Your involvement includes sharing information from your medical records and completing two short questionnaires about your health history. You'll also donate blood and/or saliva samples, and optionally provide a sample of your tumor tissue if it's safe to do so. The study continues until it closes or you decide to withdraw, with blood draws spread over several weeks.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
United States
Sponsor
Dana-Farber Cancer Institute
Enrollment target
~500 participants
Started
January 2023
Primary completion
August 2027
Age range
15 Years and older
Last updated on clinicaltrials.gov in October 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Pasi A Janne, MD, PhD
Dana-Farber Cancer Institute
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.